In the treatment of HER2-positive gastric cancer (GC), CAR-T cells engineered to target this antigen effectively eliminated HER2-positive tumour cells derived from patients, resulting in improved therapeutic outcomes and prognosis. This evidence concerns the gene ERBB2 and neoplasm.